Loading organizations...

§ Private Profile · 1209 North Orange Street, Wilmington, Delaware 19801, USA
Langaware is a technology company.
Langaware provides diagnostic technology focused on the early detection and ongoing monitoring of neurodegenerative diseases. The company employs advanced artificial intelligence to analyze digital biomarkers derived from language and speech patterns. This approach enables a non-invasive method for identifying subtle changes indicative of cognitive and mental health conditions.
The company was founded in 2019 by Vassiliki Rentoumi. The founding insight centered on the potential of leveraging sophisticated AI and linguistic analysis to identify key digital biomarkers that precede clinical symptoms of various neurological disorders, offering a proactive approach to health screening.
Their product is designed for healthcare providers seeking efficient and accessible tools for cognitive and mental health screening. Langaware envisions transforming the landscape of early disease detection, striving to offer unparalleled accuracy, speed, and convenience to improve patient outcomes through timely intervention.
Langaware has raised $4.7M across 4 funding rounds.
Langaware has raised $4.7M in total across 4 funding rounds.
# LANGaware: High-Level Overview
LANGaware is an AI-driven healthcare technology company that uses voice and speech biomarkers to enable early detection of cognitive and mental health disorders.[1] Founded in 2019 and based in Athens, Greece, the company has developed a proprietary platform that analyzes language, voice, and speech patterns to provide objective, rapid screening for conditions including mild cognitive impairment, Alzheimer's disease, and depression.[1][4] The platform delivers diagnostic decision support within three minutes by analyzing audio samples from simple speaking tasks, helping healthcare providers, payors, and life sciences companies reduce time-to-diagnosis, minimize unnecessary treatments, and improve patient outcomes.[4]
LANGaware serves a diverse customer base spanning healthcare providers, health systems, pharmaceutical companies, payors, and corporate wellness programs.[1][4] The company's core value proposition centers on reducing false positives and unnecessary treatments through objective, AI-powered assessment tools that integrate seamlessly into existing clinical workflows. As of mid-2025, LANGaware has raised $3.78 million in seed-stage funding, with its most recent round of $2.09 million occurring approximately five months prior.[1]
# Origin Story
LANGaware was founded in 2019 by Dr. Vassiliki Rentoumi, a researcher with expertise in computational linguistics, natural language processing, and machine learning.[3] The company emerged as a spinoff from the Greek National Center for Scientific Research "Demokritos" and St. George University Hospital in London, combining academic rigor with clinical validation from the outset.[3] This institutional foundation enabled the platform to be rigorously tested in both clinical and virtual care settings across the United States and Greece before broader commercialization.[3]
The company's early momentum was bolstered by its inclusion in the Endeavour Greece scaleup program, which provided support during the critical early scaling phase.[3] By January 2024, LANGaware had established a significant partnership with Premier, Inc.'s PINC AI Applied Sciences division, gaining access to real-world data from 45 percent of U.S. hospital discharges and enabling collaboration on novel therapeutic development for neurodegenerative and behavioral health diseases.[2]
# Core Differentiators
# Role in the Broader Tech Landscape
LANGaware operates at the intersection of three powerful trends: the AI-driven transformation of healthcare diagnostics, the growing emphasis on early intervention and preventive care, and the shift toward objective, data-driven clinical decision-making. The company addresses a critical market need—cognitive and mental health conditions are often underdiagnosed or diagnosed late, resulting in delayed treatment and higher healthcare costs.[3]
The timing is particularly favorable given healthcare systems' urgent need to reduce diagnostic burden while improving accuracy. With aging populations driving increased prevalence of neurodegenerative diseases and mental health challenges gaining prominence in clinical practice, demand for scalable, objective screening tools is accelerating.[1][3] LANGaware's partnerships with major healthcare infrastructure players like Premier Inc. signal institutional validation and provide pathways to rapid market penetration across health systems and life sciences companies.
The company's approach also influences broader ecosystem thinking around biomarker discovery and AI-enabled diagnostics, demonstrating how voice and speech analysis—previously underutilized in clinical settings—can serve as accessible, non-invasive diagnostic signals.
# Quick Take & Future Outlook
LANGaware is well-positioned to capture significant market share in the cognitive and mental health screening space, particularly as healthcare systems prioritize early detection and cost reduction. The company's recent funding round and strategic partnerships suggest momentum toward scaling clinical adoption and expanding its disease detection capabilities.
Key inflection points to watch include the launch of software version 2.0, expansion of anxiety detection and other new disease modules, and deepening integration with major health systems through the Premier partnership. As AI-driven diagnostics become standard in clinical workflows, LANGaware's combination of clinical validation, rapid deployment, and objective biomarker technology positions it as a foundational player in transforming how cognitive and mental health conditions are identified and managed—ultimately reducing healthcare burden while improving patient outcomes at scale.
Langaware has raised $4.7M in total across 4 funding rounds.
Langaware's investors include Metavallon VC, Epagon VC, Georgios Papadopoulos.
Langaware has raised $4.7M across 4 funding rounds. Most recently, it raised $2.1M Seed in October 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 4, 2023 | $2.1M Seed | — | Metavallon VC | Announced |
| Dec 1, 2021 | $2M Seed | — | Epagon VC, Georgios Papadopoulos | Announced |
| Jul 1, 2020 | $570K Seed | — | Epagon VC, Georgios Papadopoulos | Announced |
| Dec 1, 2019 | $75K Seed | — | Epagon VC | Announced |